• Cabinet has approved a health sector regulatory reform package covering ten categories of fees and licences, including reductions or removals affecting pharmacies, wholesalers, hospitals, laboratories, nurses, pharmacists, medical practitioners, and students
• Key measures include the abolition of HPA licences for pharmaceutical and manufacturing wholesalers, abolition of MCAZ pharmacy licence fees,  cut in HPA licensing fees, pharmaceutical manufacturing licence fees, and a cap of US$100 on private hospital approval letter fees
• The reforms reduce compliance costs and may support investment, formalisation, and medicine availability, but they do not address deeper health-sector constraints such as salaries, working conditions, equipment availability, public infrastructure, and professional emigration

Harare- The Cabinet has approved a health sector regulatory reform package spanning ten categories of fees and licences, announced by Finance Minister Mthuli Ncube on 12 May 2026. The measures include the abolition of Health Professions Authority licences for pharmaceutical and manufacturing wholesalers, abolition of Medicines Control Authority of Zimbabwe pharmacy licence fees, abolition of Medical and Dental Practitioners Council of Zimbabwe practising certificate fees for students, a 20 to 30% reduction in HPA licensing fees for medical service providers including hospitals and laboratories, a 25% reduction in MCAZ pharmaceutical manufacturing licence fees, a reduction in medicine registration fees, a reduction in MDPCZ practising certificate fees for practitioners, capping of private hospital approval letter fees at US$100, a 25% reduction in medical laboratory and clinical scientist registration fees, a 20% reduction in Nurses Council registration and practising fees, and an up to 50% reduction in Pharmacists Council registration and practising fees.

 These interventions will lower the cost of establishing and operating healthcare facilities, encourage investment in both public and private healthcare provision, improve the availability and affordability of essential medicines and services, support the training and entry of health professionals, strengthen institutional capacity, enhance service delivery, and improve public health outcomes.

These are substantial ambitions. Assessing them requires separating the measures that address specific, identifiable barriers from those whose connection to the stated outcomes is more indirect.

 The abolition of HPA licences for pharmaceutical and manufacturing wholesalers is the measure with the clearest supply-side logic. Wholesaler licensing requirements imposed compliance costs on formal medicine distributors without necessarily improving the quality or safety of the medicines they distributed, since product quality is regulated separately through MCAZ product registration requirements that remain in place. The abolition of the wholesaler licence therefore removes a cost barrier to formal distribution market entry without removing the product quality safeguards that protect patients. More formal distributors in the market should mean more competition, better medicine availability, and improved supply chain traceability.

On the other hand, the abolition of MCAZ pharmacy licence fees removes a cost barrier to formal pharmacy establishment. Zimbabwe has a documented shortage of formal pharmacies, particularly outside major urban centres, and the cost of regulatory compliance has been a factor in the economics of pharmacy operation that has deterred establishment in lower-income and rural areas. Removing the licence fee does not transform the full economics of rural pharmacy, which also involves premises costs, stock financing, and qualified staff, but it removes one cost item from a calculation that was already marginal for many potential operators.

Meanwhile, the 25% reduction in MCAZ pharmaceutical manufacturing licence fees matters for domestic medicine production. Zimbabwe has policy objectives around reducing dependence on imported medicines and building local manufacturing capacity. Licence fees that increase the operating cost of domestic manufacturers relative to importers work against that objective. Reducing them is directionally correct.

The abolition of student practising certificate fees for medical and dental students addresses a specific financial burden at a specific career stage. Students completing internship and community service requirements have been required to pay practising certificate fees while earning government stipends or salaries that the press statement implicitly acknowledges are insufficient to make these costs trivial. Removing the fee at this stage reduces friction for new entrants into the formal health workforce.

 Elsewhere, reductions in Nurses Council, MDPCZ, Pharmacists Council, medical laboratory, and clinical scientist registration and practising fees reduce the annual cost of maintaining professional registration for practitioners across multiple health disciplines. The government frames these as measures that will support the training and entry of health professionals and strengthen institutional capacity.

What the press statement does not address is the relationship between these fee reductions and the structural pressures that drive health professional emigration from Zimbabwe. Professional registration fees are a component of the cost of practising in Zimbabwe, but they are not the primary determinant of whether a trained health professional chooses to remain in the country or seek employment elsewhere.

The press statement is silent on salaries, on working conditions, on the availability of medicines and equipment in public facilities, and on the infrastructure and supply chain deficits that affect the ability of health professionals to practise their disciplines effectively. These are the factors that health sector stakeholders have consistently identified as the primary drivers of workforce challenges. The regulatory reforms  address the regulatory cost dimension of a problem whose most significant dimensions lie elsewhere.

The capping of private hospital approval letter fees at US$100 creates cost certainty at one point in the private hospital establishment process. This is a measurable improvement over a previous situation in which approval letter fees were not standardised and were therefore subject to the discretion of approving authorities. Predictability in regulatory costs is a legitimate and important factor in investment decisions for capital-intensive sectors, and the capping addresses that predictability concern directly.

These measures will over time strengthen institutional capacity, enhance service delivery, and improve public health outcomes. Regulatory fee reductions create more favourable conditions for investment and professional participation in the health sector. Whether those conditions translate into the outcomes described depends on complementary actions, including capital investment in public health infrastructure and workforce compensation reform, that press statement does not announce.

 The reforms are real, they are coherent within their scope, and several of them address specific documented barriers with well-designed interventions. Their limitation is that they are partial, addressing the regulatory cost surface of a problem whose structural core requires a different and more expensive set of solutions.

Equity Axis News